中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
HIV
Partnership
Investors
Financials & Filing
Presentation Materials
News
2020
2019
2018
2017
2016
2015
2014
Careers
Investors
Financials & Filing
Presentation Materials
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
2020-07-03
List of Directors and Their Role and Function
2020-06-30
Resignation of Independent Non-Executive Director; Change in Composition of the Board Committees
2020-06-30
Voluntary Announcement - ASC40 (TVB2640) Significantly Reduced Liver Fat with a 61% Responder Rate in Phase 2 NASH Trial
2020-06-17
Poll Results of Annual General Meeting Held on June 15 2020
2020-06-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020
2020-06-02
Clarification Announcement - Form of Proxy for the 2020 Annual General Meeting
2020-05-28
Voluntary Announcement - Approval of Clinical Trials of Non-alcoholic Steatohepatitis Drug ASC41, a THR-beta Agonist
2020-05-13
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
2020-05-13
Form of Proxy for the 2020 Annual General Meeting
2020-05-13
«
2
3
4
5
»
